Clinical trial registry record

Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 10, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02812992
Last registry update
August 10, 2021
Status
Completed
Phase
Phase 4
Sponsor
AIO-Studien-gGmbH
Enrollment
32
Countries
Germany
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
32
Population
ALL · 70 Years
Duration
2016-06-01 to 2021-02-01
Intervention
Nab-paclitaxel; Gemcitabine; Best Supportive Care
Comparator
GO-GO arm; SLOW-GO arm; FRAIL arm
Outcomes measured
Barthel's ADL [Barthel's scale in activities of daily living] — 4 weeks; CGA [Comprehensive Geriatric Assessment] — 4 weeks; ECOG [Eastern Cooperative Oncology Group] — 4 weeks; ADL (Barthel) [Activities of Daily Living] — 4 weeks; IADL (Lawton/Browdy) [Instrumental Activities of Daily Living] — 4 weeks; G8-Questionnaire — 4 weeks; CR [Complete Response] — 12 months; PR [Partial Response] — 12 months; DCR [Disease Control Rate] — 12 months; ORR [Objective Response Rate] — 12 months; AEs/SAEs [Adverse Events/Serious Adverse Events] — 12 months; PFS [Progression Free Survival] — 12 months; OS [Overall Survival] — 12 months; Percentage of patients receiving at least one chemotherapy in each treatment group — 12 months; Percentage of patients escalating treatment — 12 months; Duration of treatment — 12 months; Cumulative dose — 12 months; QoL [Quality of Life] — 12 months; Discrepancy between CGA strata estimation by the investigator and true CGA assessment — 12 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON